Disease · MONDO_0005283

retinal disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. retinal disorder. Diseases, record MONDO_0005283. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005283

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: retinal disorder; Open Targets
Open Targets ID: MONDO_0005283; Open Targets
Other names: eye disease of retina, retina eye disease, retinal disease, retinopathy; Open Targets
Disease Ontology: DOID:5679; Disease Ontology
MeSH: D012164; MeSH
NCI Thesaurus: C26875; NCI Thesaurus
NCI Thesaurus: C62601; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 9 drugs, from EMA Human Drugs, at withdrawal; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OCRIPLASMIN	CHEMBL2095222	Protein	Approval	EMA Human Drugs, at withdrawal	1	0	0	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUOCINOLONE ACETONIDE	CHEMBL989	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
RANIBIZUMAB	CHEMBL1201825	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
AFLIBERCEPT	CHEMBL1742982	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
RST-001	CHEMBL5095289		Phase 1/2	TTD	1	0	0	Drugs and targets
TRIAMCINOLONE ACETONIDE	CHEMBL1504	Small molecule	Unknown	ClinicalTrials.gov	2	2	2	Drugs and targets
CARBOXYMETHYLCELLULOSE SODIUM	CHEMBL2109001		Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets
INSULIN HUMAN	CHEMBL1201631	Protein	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets42

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
VEGFA	Vascular endothelial growth factor A, long form	3	Vascular endothelial growth factor A inhibitor	Phase 2/3	https://conductscience.org/library/genes/7422	Drugs and targets
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 2/3	https://conductscience.org/library/genes/2908	Drugs and targets
COL11A1	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/1301	Drugs and targets
COL11A2	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/1302	Drugs and targets
COL15A1	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/1306	Drugs and targets
COL18A1	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/80781	Drugs and targets
COL1A1	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/1277	Drugs and targets
COL1A2	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/1278	Drugs and targets
COL24A1	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/255631	Drugs and targets
COL27A1	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/85301	Drugs and targets

1 to 10 of 42

See all 42 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02138006	Long-term Effects of Intensive Insulin Treatment in Type 1 Diabetes	Not applicable	102	2015-12-21	Coronary Heart Disease, Stroke, Renal Failure	INSULIN HUMAN	Its record names the disease	ClinicalTrials.gov
NCT02222610	Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.	Phase 2	40	2021-03-25	Radiation Retinopathy	RANIBIZUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT05496530	Custom Needle Preparation for Suprachoroidal Steroid Injection (One Year Results)	Not applicable	100		Diabetic Macular Edema, Vogt Koyanagi Harada Disease, Retinal Vein Occlusion	TRIAMCINOLONE ACETONIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03085784	Intravitreal Aflibercept Injection for Radiation Retinopathy Trial	Phase 2	40		Radiation Retinopathy	AFLIBERCEPT	Open Targets' reading of its record	ClinicalTrials.gov
NCT05288192	Changes After Suprachoroidal Injection.	Not applicable	30		Retina; Change, Intraocular Pressure, Cataract, Macular Edema	TRIAMCINOLONE ACETONIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00750399	Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma	Phase 1	10		Radiation Retinopathy, Choroidal Melanoma	RANIBIZUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01334879	High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy	Phase 1	10		Radiation Retinopathy	RANIBIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01579760	Intravitreal Aflibercept Injection for Radiation Retinopathy	Phase 1	9		Radiation Retinopathy, Macular Edema	AFLIBERCEPT	Open Targets' reading of its record	ClinicalTrials.gov
NCT03238157	Steroids for Early Treatment of Radiation Retinopathy	Phase 2/3	0		Radiation Retinopathy	FLUOCINOLONE ACETONIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00600262	Intravitreal Bevacizumab for Diabetic Retinopathy	Phase 2/3			Severe Nonproliferative, Proliferative Diabetic Retinopathy, Active Photocoagulated Diabetic Retinopathy	BEVACIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Intensive Insulin Treatment vs Standard Insulin Treatment: Cardiovascular Mortality	7 of 48	11 of 54	102	NCT02138006	Trial comparisons
Intensive Insulin Treatment vs Standard Insulin Treatment: Morbidity of Cardiovascular Complications	6 of 48	11 of 54	102	NCT02138006	Trial comparisons
Intensive Insulin Treatment vs Standard Insulin Treatment: serious adverse events	0 of 48	0 of 54	102	NCT02138006	Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
20142553	RESULT	1	PubMed
34463842	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005283

GET https://conductscience.org/api/diseases/v1/MONDO_0005283/targets?page=2

API reference For AI assistants